Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
HOME > ACADEMIA
ACADEMIA
- CRND Initiates Clinical Research, Showing Willingness for Company-Sponsored Studies
September 6, 2012
- Incidence of CVD Decreases More in High-Risk Patients with Lower LDL-C during Pravastatin Treatment
July 26, 2012
- 95% of Japanese-Bound Online Drug Sales “Rogue”: LegitScript Survey
July 26, 2012
- Takeda’s TAK-070 for AD Worthy of Clinical Trial: Prof. Iwatsubo of Univ. of Tokyo Hospital
July 18, 2012
- Inlyta Can Be 1st-Choice in 2nd-Line Therapy: Prof. Uemura of Kinki Univ.
July 13, 2012
- Minirinmelt Most Effective for Nocturnal Enuresis, But Precaution for Water Intoxication Needed: Prof. Kaneko
July 11, 2012
- Drug Damage Watchdog Calls for Halt to Easing of Safety Management Procedures for Thalidomide
June 28, 2012
- Univ. of Tokyo Hospital’s New “Phase I Unit” to Initiate Trials for Takeda’s TAK-070 for AD
June 28, 2012
- JSGM Discuss Prices for Long-Listed Products and GEs, Say Unified Prices Could Ruin GE Business
June 26, 2012
- RIKEN, NCC Succeed at Visualizing Kinetics of Trastuzumab in HER2-Positive Breast Cancer Patients
June 7, 2012
- JSN Revises CKD Guidelines; Changes Severity Classifications
May 31, 2012
- Serious ADR for Abatacept shows 2.4%, Lower Than Other RA Drugs: All-Case PMS Interim Analysis
May 7, 2012
- St. Marianna University School of Medicine Hospital to Introduce CDTM, Protocols for Pharmacists to Determine Prescriptions
April 27, 2012
- Remission Rate Equal in Antirheumatic Drugs, Anti-TNF Drugs in JaSTAR’s Interim Analysis
April 26, 2012
- Adoption of NGSP Values for HbA1c Measurement to “Enable Japan’s Leadership in Clinical Trials”: Prof. Kadowaki
April 10, 2012
- Generic Name Prescriptions Rapidly Rise on New Premium, Tokyo Pharmaceutical Association Issues Warning
April 9, 2012
- Industry-Academia-Government Research Group to Build Adjuvant Database, Support Next-Generation Vaccine Development
March 29, 2012
- Prof. Nakamura Renews Call for Establishment of Drug Discovery Support Organization
March 9, 2012
- Insulin Stockpiles Insufficient at Medical Facilities in Disaster-Hit Areas: JDS Survey
March 6, 2012
- Osaka Medical Center President Hori says “Once-Daily Xarelto is Easy to Take”
February 27, 2012
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…